New Targeted Therapy Approved for Chemotherapy-Resistant Ovarian Cancer on the NHS

The National Institute for Health and Care Excellence (NICE) has announced a significant milestone in oncology, approving the first new treatment for platinum-resistant ovarian cancer in more than two decades. This development offers a new therapeutic pathway for patients whose cancer has stopped responding to standard chemotherapy regimens.

Understanding the New Treatment

The newly approved medication is mirvetuximab soravtansine (marketed as Elahere by AbbVie). This treatment represents a shift toward precision medicine, utilizing a targeted approach to address cancer cells directly. Unlike traditional chemotherapy, which can affect healthy cells alongside cancerous ones, this therapy binds to specific proteins on the surface of cancer cells to deliver its treatment payload.

According to guidance published by NICE on June 4, 2024, the treatment is recommended for patients with folate receptor-alpha-positive (FRα-positive) platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

The Role of Precision Medicine

The shift toward precision medicine is central to this approval. To determine eligibility, patients will undergo a biomarker test on a sample of their tumour tissue. This test identifies the presence of the FRα protein, ensuring the treatment is directed toward those most likely to experience a clinical benefit.

Michal Sladkowski, vice chair elect of the British Oncology Pharmacy Association (BOPA), noted that the recommendation “reflects the increasing role of precision medicine in ovarian cancer, where biomarker testing is helping us match patients to treatments that are most likely to benefit them.”

He added: “For eligible women whose tumours express folate receptor-alpha (FRα), mirvetuximab soravtansine offers a welcome new option at a stage of disease where additional effective treatments are urgently needed.”

Impact on Patient Access

The introduction of this therapy is expected to provide a crucial option for a patient population with limited alternatives. NICE anticipates that approximately 270 patients will be eligible for the treatment within the first year of rollout. As access to the necessary FRα biomarker testing expands, this figure is projected to rise to approximately 420 patients by the third year.

Committee papers noted that this targeted therapy may be particularly beneficial for women from South Asian, Caribbean, and African backgrounds, who have been identified as more likely to be diagnosed with these gynaecological cancers at a later stage.

Key Takeaways

• First in 20 years: This is the first new treatment for platinum-resistant ovarian cancer approved for NHS use in over two decades.
• Targeted mechanism: Mirvetuximab soravtansine acts as a precision therapy, binding directly to FRα-positive cancer cells.
• Eligibility: Patients must test positive for the folate receptor-alpha biomarker via a tumour tissue sample to qualify for the treatment.
• Clinical reach: Access is expected to grow from an initial 270 eligible patients in the first year to 420 by the third year as testing infrastructure scales.

This approval marks a pivotal step in expanding the toolkit available to oncologists, offering renewed hope for patients navigating advanced stages of ovarian, fallopian tube, or primary peritoneal cancer.